{
    "root": "5bd9a571-7061-4cc7-bda8-18a9976dd427",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SOHONOS",
    "value": "20250318",
    "ingredients": [
        {
            "name": "palovarotene",
            "code": "28K6I5M16G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_188559"
        },
        {
            "name": "croscarmellose sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "sodium lauryl sulfate",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "propylene glycol",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "shellac",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "sohonos indicated reduction volume new heterotopic ossification adults pediatric patients aged 8 years older females 10 years older males fibrodysplasia ossificans progressiva ( fop ) .",
        "doid_entities": [
            {
                "text": "fibrodysplasia ossificans progressiva (DOID:13374)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13374"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "obtain negative pregnancy test females reproductive potential initiation sohonos ( 2.1 ) recommended includes chronic daily dose , increased flare-up symptoms ( 2.2 ) adults pediatric patients 14 years older : recommended 5 mg daily , increase dose time flare-up 20 mg daily 4 weeks , followed 10 mg daily 8 weeks total 12 weeks ( 20/10 mg flare-up treatment ) ( 2.2 ) pediatric patients 14 years : weight-adjusted daily flare-up dosing . recommended daily range 2.5 5 mg. refer table 1 full prescribing information complete pediatric dosing ( 2.2 ) take sohonos food preferably time day ( 2.3 ) . reduce dose event appropriate ( 2.4 ) full prescribing information complete dosing instructions ( 2 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "chronic daily dose",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_674965"
            }
        ]
    },
    "warningsAndPrecautions": "supplied sohonos opaque white elongated hard-gelatin capsule . sohonos available size `` 0 `` capsule supplied blister strip containing 14 capsules child resistant carton . capsule contains white off-white powder . table 8 shows capsules ' strengths , imprints , ndc numbers . table 8. capsules ' strengths , imprints , ndc numbers strength ( mg ) imprint ndc 1 pvo 1 15054-0010-1 1.5 pvo 1.5 15054-0015-1 2.5 pvo 2.5 15054-0025-1 5 pvo 5 15054-0050-1 10 pvo 10 15054-0100-1",
    "adverseReactions": "sohonos contraindicated following patients : pregnancy [ ( 5.1 ) ( 8.1 ) ] . history allergy hypersensitivity retinoids , component sohonos . anaphylaxis allergic occurred retinoids . [ description ( 11 ) ] .",
    "indications_original": "SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).",
    "contraindications_original": "Obtain a negative pregnancy test in females of reproductive potential before initiation of SOHONOS ( 2.1 ) Recommended dosage includes a chronic daily dose, which can be increased for flare-up symptoms ( 2.2 ) For adults and pediatric patients 14 years and older: Recommended dosage is 5 mg once daily, with an increase in dose at the time of a flare-up to 20 mg once daily for 4 weeks, followed by 10 mg once daily for 8 weeks for a total of 12 weeks (20/10 mg flare-up treatment) ( 2.2 ) For pediatric patients under 14 years: Weight-adjusted for daily and flare-up dosing. Recommended daily dosage range from 2.5 to 5 mg. Refer to Table 1 in Full Prescribing Information for complete pediatric dosing ( 2.2 ) Take SOHONOS with food preferably at same time each day ( 2.3 ). Reduce the dose in the event of adverse reactions as appropriate ( 2.4 ) See Full Prescribing Information for complete dosing instructions ( 2 )",
    "warningsAndPrecautions_original": "How Supplied\n                        \n                        SOHONOS is an opaque white elongated hard-gelatin capsule. SOHONOS is available in size \"0\" capsule and supplied as a blister strip containing 14 capsules in a child resistant carton. Capsule contains white to off-white powder. Table 8 shows capsules' strengths, imprints, and NDC numbers.\n                        \n                           Table 8. Capsules' Strengths, Imprints, and NDC numbers\n                           \n                           \n                           \n                           \n                              \n                                 Strength (mg)\n                                 Imprint\n                                 NDC\n                              \n                           \n                           \n                              \n                                 1\n                                 PVO 1\n                                 15054-0010-1\n                              \n                              \n                                 1.5\n                                 PVO 1.5\n                                 15054-0015-1\n                              \n                              \n                                 2.5\n                                 PVO 2.5\n                                 15054-0025-1\n                              \n                              \n                                 5\n                                 PVO 5\n                                 15054-0050-1\n                              \n                              \n                                 10\n                                 PVO 10\n                                 15054-0100-1",
    "adverseReactions_original": "SOHONOS is contraindicated in the following patients:\n                  \n                     During Pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].\n                     A history of allergy or hypersensitivity to retinoids, or to any component of SOHONOS. Anaphylaxis and other allergic reactions have occurred with other retinoids. [see Description (11)].",
    "drug": [
        {
            "name": "SOHONOS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_188559"
        }
    ]
}